炎症性肠病的达标治疗:前景、风险与前进路径
本文综述了炎症性肠病达标治疗框架的两个支柱:定义合适的治疗目标和迭代调整治疗直至达标。第一个支柱已从症状缓解深入到内镜、组织学愈合乃至透壁和分子终点,主要基于关联数据;第二个支柱证据较弱,随机试验结果不一,无症状残留炎症患者是否应优化或转换高级治疗仍无答案。
要点
- 达标治疗目标已从症状缓解深化至内镜、组织学及透壁愈合,但证据多为关联性。
- 迭代调整治疗的随机试验在未选择人群中结果不一,真实世界监测不一致。
- 无症状残留炎症患者是否应优化或转换高级治疗仍是未解临床问题。
核心结论
- 达标治疗的第一支柱(定义目标)进展显著,但第二支柱(迭代调整治疗)证据基础较弱且实施不一致。
研究设计与样本
- 综述类文章,检索范围未在摘要中明确报告。
主要发现
- 治疗目标已从症状缓解深化至内镜和组织学愈合,并向透壁和分子终点发展,主要由关联数据支持更深缓解与更好长期结局。
- 迭代治疗调整的随机试验在未选择人群中结果不一,真实世界监测仍不一致。
- 无症状残留炎症患者能否从优化或转换高级治疗中获益尚未回答。
关键数值与推荐
- 治疗目标演变包括症状缓解、内镜愈合、组织学愈合、透壁愈合和新兴分子终点。
临床怎么用
- 建议基于疾病史、炎症轨迹、治疗选择和患者偏好个体化达标治疗决策。
局限性
- 第二支柱证据有限,随机试验结果混合,真实世界监测不一致。
- 无症状残留炎症患者的管理问题未解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treat-to-target has become the organising framework for contemporary inflammatory bowel disease (IBD) management, yet its evidence base is less robust than its widespread endorsement might suggest. The approach rests on two equally essential pillars: defining the right therapeutic target, and adjusting treatment iteratively until that target is achieved. Over the past decade, the first pillar has advanced substantially: targets have deepened from symptomatic remission through endoscopic and histologic healing toward transmural and emerging molecular endpoints, supported largely by association data linking deeper remission to better long-term outcomes. The second pillar has received considerably less scrutiny. Completed randomised trials of iterative treatment adjustment have yielded mixed results in unselected populations, real-world monitoring remains inconsistent, and the most clinically pressing question, whether asymptomatic patients with residual inflammation benefit from optimising or switching advanced therapies, remains unanswered. In this review, we critically examine both pillars: the evolution and evidence base for treatment targets in IBD, the ability of current therapies to achieve them, the lessons from pivotal treat-to-target trials, and the barriers to real-world implementation. We propose a framework for individualising treat-to-target decisions based on disease history, inflammatory trajectory, therapeutic options, and patient preferences. Ongoing trials including QUOTIENT, VERDICT, and VECTORS may define whether the second pillar can be placed on as firm a footing as the first.
引用
- Singh S, Nardone OM, Allocca M, et al. TREAT-TO-TARGET IN INFLAMMATORY BOWEL DISEASE: PROMISE, PERILS, AND THE PATH FORWARD. Clin Gastroenterol Hepatol. 2026. PMID: 42829018. doi:10.1016/j.cgh.2026.09.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。